Oxford based Theolytics is leveraging a library of 100M variants of adenoviruses for a bottom up approach to oncolytic virus cancer drug development
- Feb 21, 2025
- 1 min read
CEO David Apelian describes the importance of choosing the right strain for the right type of cancer, and discusses the company's lead program for ovarian cancer.









.png)
